Am. J. Respir. Crit. Care Med., Volume 157, Number 4, April 1998, 1111-1119

Effect of Dexfenfluramine Treatment in Rats Exposed to Acute and Chronic Hypoxia

SAADIA EDDAHIBI, BERNADETTE RAFFESTIN, JEAN-MARIE LAUNAY, MARYVONNE SITBON, and SERGE ADNOT

Département de Physiologie et Institut National de la Santé et de la Recherche Médicale Unit 296, Henri Mondor, University Hospital Center, Créteil, France; Département de Physiologie, Université René Descartes, Hôpital Ambroise Paré, Boulogne, France; and Département de Biochimie, Université Paris VII, Hôpital Lariboisiére, Paris, France

The anorexiant dexfenfluramine, which inhibits 5-hydroxytryptamine (5-HT) uptake, has been associated with an increase in the relative risk of developing primary pulmonary hypertension. The aim of this study was to investigate in rats whether dexfenfluramine (1) alters the pulmonary vasomotor effects of 5-HT and (2) aggravates the development of pulmonary hypertension during exposure to various levels of chronic hypoxia. In isolated lungs from normoxic rats, dexfenfluramine up to 10⁴ M did not elicit any vasoactive effects, and neither did pretreatment with dexfenfluramine (10⁵ M in the perfusate) modify the vasoactive effects of 5-HT. In normoxic conscious rats, dexfenfluramine given intravenously potentiated the pulmonary pressor response to acute hypoxia (10% O₂). In rats chronically treated with dexfenfluramine during a 2-wk exposure to 15% or 10% O₂ , plasma 5-HT concentrations were significantly increased compared with hypoxic controls, whereas no differences were found for pulmonary artery pressure, right ventricular hypertrophy, or pulmonary vessel muscularization. In contrast, a continuous 5-HT infusion providing a sustained increase in plasma 5-HT levels was associated with increased muscularization of distal pulmonary arteries in response to 10% O₂. Simultaneous administration of dexfenfluramine prevented the effect of exogenous 5-HT on vascular remodeling. Our findings show that dexfenfluramine does not potentiate the development of pulmonary hypertension in rats exposed to chronic hypoxia, despite its effect on plasma 5-HT concentrations.

This article has been cited by other articles:

				Y. Dempsie, I. Morecroft, D. J. Welsh, N. A. MacRitchie, N. Herold, L. Loughlin, M. Nilsen, A. J. Peacock, A. Harmar, M. Bader, et al. Converging Evidence in Support of the Serotonin Hypothesis of Dexfenfluramine-Induced Pulmonary Hypertension With Novel Transgenic Mice Circulation, June 3, 2008; 117(22): 2928 - 2937. [Abstract] [Full Text] [PDF]

				E. K. Weir, M. Obreztchikova, and Z. Hong Fenfluramine: riddle or Rosetta stone? Eur. Respir. J., February 1, 2008; 31(2): 232 - 235. [Full Text] [PDF]

				D. Zolkowska, M. H. Baumann, and R. B. Rothman Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 791 - 797. [Abstract] [Full Text] [PDF]

				A. Varghese, Z. Hong, and E. K. Weir Serotonin-Induced Inhibition of KV Current: A Supporting Role in Pulmonary Vasoconstriction? Circ. Res., April 14, 2006; 98(7): 860 - 862. [Full Text] [PDF]

				S. Rezaie-Majd, J. Murar, D. P. Nelson, R. F. Kelly, Z. Hong, I. M. Lang, A. Varghese, and E. K. Weir Increased release of serotonin from rat ileum due to dexfenfluramine Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1209 - R1213. [Abstract] [Full Text] [PDF]

				E. K. Weir, Z. Hong, and A. Varghese The Serotonin Transporter: A Vehicle to Elucidate Pulmonary Hypertension? Circ. Res., May 14, 2004; 94(9): 1152 - 1154. [Full Text] [PDF]

				E. Marcos, S. Adnot, M. H. Pham, A. Nosjean, B. Raffestin, M. Hamon, and S. Eddahibi Serotonin Transporter Inhibitors Protect against Hypoxic Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 487 - 493. [Abstract] [Full Text] [PDF]

				Y. Mitani, A. Mutlu, J. C. Russell, D. N. Brindley, J. DeAlmeida, and M. Rabinovitch Dexfenfluramine protects against pulmonary hypertension in rats J Appl Physiol, November 1, 2002; 93(5): 1770 - 1778. [Abstract] [Full Text] [PDF]

				S. Belohlavkova, J. Simak, A. Kokesova, O. Hnilickova, and V. Hampl Fenfluramine-induced pulmonary vasoconstriction: role of serotonin receptors and potassium channels J Appl Physiol, August 1, 2001; 91(2): 755 - 761. [Abstract] [Full Text] [PDF]

				S. Eddahibi, S. Adnot, E. Frisdal, M. Levame, M. Hamon, and B. Raffestin Dexfenfluramine-Associated Changes in 5-Hydroxytryptamine Transporter Expression and Development of Hypoxic Pulmonary Hypertension in Rats J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 148 - 154. [Abstract] [Full Text]

				S. Eddahibi, V. Fabre, C. Boni, M. P. Martres, B. Raffestin, M. Hamon, and S. Adnot Induction of Serotonin Transporter by Hypoxia in Pulmonary Vascular Smooth Muscle Cells : Relationship With the Mitogenic Action of Serotonin Circ. Res., February 19, 1999; 84(3): 329 - 336. [Abstract] [Full Text] [PDF]